Vlatkovic N - Search Results

1

Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.

Wilkie MD, Lau AS, Vlatkovic N, Jones TM, Boyd MT. Wilkie MD, et al. Among authors: vlatkovic n. Oral Oncol. 2018 Aug;83:1-10. doi: 10.1016/j.oraloncology.2018.05.018. Epub 2018 Jun 2. Oral Oncol. 2018. PMID: 30098763 Review.

2

Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.

Vlatković N, El-Fert A, Devling T, Ray-Sinha A, Gore DM, Rubbi CP, Dodson A, Jones AS, Helliwell TR, Jones TM, Boyd MT. Vlatković N, et al. Cancer. 2011 Jul 1;117(13):2939-50. doi: 10.1002/cncr.25864. Epub 2011 Jan 10. Cancer. 2011. PMID: 21692053 Free article.

3

Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications.

Wilkie M, Lau A, Vlatkovic N, Jones T, Boyd M. Wilkie M, et al. Among authors: vlatkovic n. Lancet. 2015 Feb 26;385 Suppl 1:S101. doi: 10.1016/S0140-6736(15)60416-0. Lancet. 2015. PMID: 26312831

4

TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies.

Wilkie MD, Anaam EA, Lau AS, Rubbi CP, Jones TM, Boyd MT, Vlatković N. Wilkie MD, et al. Among authors: vlatkovic n. Cancer Lett. 2020 May 28;478:107-121. doi: 10.1016/j.canlet.2020.02.032. Epub 2020 Feb 28. Cancer Lett. 2020. PMID: 32113989 Free PMC article.

5

Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines.

Wilkie MD, Anaam EA, Lau AS, Rubbi CP, Vlatkovic N, Jones TM, Boyd MT. Wilkie MD, et al. Among authors: vlatkovic n. Cancers (Basel). 2021 Sep 28;13(19):4836. doi: 10.3390/cancers13194836. Cancers (Basel). 2021. PMID: 34638320 Free PMC article.

6

p53 regulation and function in renal cell carcinoma.

Warburton HE, Brady M, Vlatković N, Linehan WM, Parsons K, Boyd MT. Warburton HE, et al. Among authors: vlatkovic n. Cancer Res. 2005 Aug 1;65(15):6498-503. doi: 10.1158/0008-5472.CAN-05-0017. Cancer Res. 2005. PMID: 16061625

7

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Noon AP, Vlatković N, Polański R, Maguire M, Shawki H, Parsons K, Boyd MT. Noon AP, et al. Among authors: vlatkovic n. Cancer. 2010 Feb 15;116(4):780-90. doi: 10.1002/cncr.24841. Cancer. 2010. PMID: 20052733 Free PMC article. Review.

8

Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all.

Vlatković N, Crawford K, Rubbi CP, Boyd MT. Vlatković N, et al. Curr Pharm Des. 2011;17(6):618-30. doi: 10.2174/138161211795222568. Curr Pharm Des. 2011. PMID: 21391912 Review.

9

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.

Noon AP, Polański R, El-Fert AY, Kalirai H, Shawki H, Campbell F, Dodson A, Eccles RM, Lloyd BH, Sibson DR, Coupland SE, Lake SL, Parsons K, Vlatković N, Boyd MT. Noon AP, et al. Among authors: vlatkovic n. BJU Int. 2012 Apr;109(8):1250-7. doi: 10.1111/j.1464-410X.2011.10433.x. Epub 2011 Jul 14. BJU Int. 2012. PMID: 21756282

10

Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.

Vlatković N, Boyd MT, Rubbi CP. Vlatković N, et al. Cell Mol Life Sci. 2014 Mar;71(5):771-91. doi: 10.1007/s00018-013-1361-x. Epub 2013 May 18. Cell Mol Life Sci. 2014. PMID: 23685903 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters